Page 128 - Read Online

Gomaa et al. Advanced HCC: current and potential therapies

with sorafenib (REACH): a randomised, double-blind, multicentre, Khoueiry A. Nivolumab dose escalation and expansion in patients
phase 3 trial. Lancet Oncol 2015;16:859-70. with advanced hepatocellular carcinoma (HCC): the CheckMate 040
33. Zhu AX, Kudo M, Assenat E, Cattan S, Kang YK, Lim HY, Poon study. Available from: https://www.mdlinx.com/gastroenterology/
RT, Blanc JF, Vogel A, Chen CL. Effect of everolimus on survival conference-abstract.cfm/60392/?nonus=0&searchstring=&coverage_
in advanced hepatocellular carcinoma after failure of sorafenib: the day=0&page=2. [Last accessed on June 1, 2017].
EVOLVE-1 randomized clinical trial. JAMA 2014;312:57-67. 49. Sangro B, Gomez-Martin C, de la Mata M, Iñarrairaegui M,
34. Llovet JM, Decaens T, Raoul JL, Boucher E, Kudo M, Chang C, Garralda E, Barrera P, Riezu-Boj JI, Larrea E, Alfaro C, Sarobe P.
Kang YK, Assenat E, Lim HY, Boige V. Brivanib in patients with A clinical trial of CTLA-4 blockade with tremelimumab in patients
advanced hepatocellular carcinoma who were intolerant to sorafenib with hepatocellular carcinoma and chronic hepatitis C. J Hepatol
or for whom sorafenib failed: results from the randomized phase III 2013;59:81-8.
BRISK-PS study. J Clin Oncol 2013;31:3509-16. 50. Fuchs CS, Clark JW, Ryan DP, Kulke MH, Kim H, Earle CC,
35. Bruix J, Sherman M. Management of hepatocellular carcinoma: an Vincitore M, Mayer RJ, Stuart KE. A phase II trial of gemcitabine
update. Hepatology 2011;53:1020-2. in patients with advanced hepatocellular carcinoma. Cancer
36. Strumberg D, Schultheis B. Regorafenib for cancer. Expert Opin 2002;94:3186-91.
Investig Drugs 2012;21:879-89. 51. Yeo W, Mok TS, Zee B, Leung TW, Lai PB, Lau WY, Koh J, Mo
37. Santoro A, Rimassa L, Borbath I, Daniele B, Salvagni S, Van FK, Yu SC, Chan AT, Hui P, Ma B, Lam KC, Ho WM, Wong HT,
Laethem JL, Van Vlierberghe H, Trojan J, Kolligs FT, Weiss A. Tang A, Johnson PJ. A randomized phase III study of doxorubicin
Tivantinib for second-line treatment of advanced hepatocellular versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil
carcinoma: a randomised, placebo-controlled phase 2 study. Lancet (PIAF) combination chemotherapy for unresectable hepatocellular
Oncol 2013;14:55-63. carcinoma. J Natl Cancer Inst 2005;97:1532-8.
38. Zhu AX, Ryoo BY, Yen CJ, Kudo M, Poon RT-P, Pastorelli D, Blanc 52. de Verdià A. Reversion of multidrug resistance with
JF, Chung HC, Baron AD, Pfiffer TEF. Ramucirumab (RAM) as polyalkylcyanoacrylate nanoparticles: towards a mechanism of
second-line treatment in patients (pts) with advanced hepatocellular action. Br J Cancer 1997;76:198.
carcinoma (HCC): analysis of patients with elevated α-fetoprotein 53. Kudo M, Moriguchi M, Numata K, Hidaka H, Tanaka H, Ikeda M,
(AFP) from the randomized phase III REACH study. Am Soc Clinl Kawazoe S, Ohkawa S, Sato Y, Kaneko S, Furuse J, Takeuchi M,
Oncol 2015;35:abstr4108. Fang X, Date Y, Takeuchi M, Okusaka T. S-1 versus placebo in
39. Zhu AX, Baron AD, Malfertheiner P, Kudo M, Kawazoe S, Pezet patients with sorafenib-refractory advanced hepatocellular carcinoma
D, Weissinger F, Brandi G, Barone CA, Okusaka T. Ramucirumab (S-CUBE): a randomised, double-blind, multicentre, phase 3 trial.
as second-line treatment in patients with advanced hepatocellular Lancet Gastroenterol Hepatol 2017;2:407-17.
carcinoma: analysis of REACH trial results by Child-Pugh score. 54. Qin S, Bai Y, Lim HY, Thongprasert S, Chao Y, Fan J, Yang TS,
JAMA Oncol 2017;3:235-43. Bhudhisawasdi V, Kang WK, Zhou Y. Randomized, multicenter,
40. Finn RS. Current and future treatment strategies for patients with open-label study of oxaliplatin plus fluorouracil/leucovorin versus
advanced hepatocellular carcinoma: role of mTOR inhibition. Liver doxorubicin as palliative chemotherapy in patients with advanced
Cancer 2012;1:247-56. hepatocellular carcinoma from Asia. J Clin Oncol 2013;31:3501-8.
41. Kang YK, Yau T, Park JW, Lim H, Lee TY, Obi S, Chan S, Qin 55. Liu L, Zheng Y, Han L, Qin S. Efficacy and safety of oxaliplatin-
S, Kim R, Casey M. Randomized phase II study of axitinib versus based chemotherapy for advanced primary hepatic carcinoma: a
placebo plus best supportive care in second-line treatment of systemic review and meta analysis of prospective studies. Linchuang
advanced hepatocellular carcinoma. Ann Oncol 2015;26:2457-63. Zhongliuxue Zazhi 2015;20:769-79.
42. Qin S. Apatinib in Chinese patients with advanced hepatocellular 56. Petrelli F, Coinu A, Borgonovo K, Cabiddu M, Ghilardi M, Lonati V,
carcinoma: a phase II randomized, open-label trial. Am Soc Clin Barni S. Oxaliplatin-based chemotherapy: a new option in advanced
Oncol 2014;32 suppl:abstr4019. hepatocellular carcinoma. a systematic review and pooled analysis.
43. O’Reilly KE, Rojo F, She Q-B, Solit D, Mills GB, Smith D, Lane Clin Oncol 2014;26:488-96.
H, Hofmann F, Hicklin DJ, Ludwig DL. mTOR inhibition induces 57. Abou-Alfa GK, Johnson P, Knox JJ, Capanu M, Davidenko I,
upstream receptor tyrosine kinase signaling and activates Akt. Lacava J, Leung T, Gansukh B, Saltz LB. Doxorubicin plus sorafenib
Cancer Res 2006;66:1500-8. vs doxorubicin alone in patients with advanced hepatocellular
44. Koeberle D, Dufour JF, Demeter G, Li Q, Ribi K, Samaras P, Saletti carcinoma: a randomized trial. JAMA 2010;304:2154-60.
P, Roth A, Horber D, Buehlmann M. Sorafenib with or without 58. Del Prete S, Montella L, Caraglia M, Maiorino L, Cennamo G,
everolimus in patients with advanced hepatocellular carcinoma Montesarchio V, Piai G, Febbraro A, Tarantino L, Capasso E.
(HCC): a randomized multicenter, multinational phase II trial (SAKK Sorafenib plus octreotide is an effective and safe treatment in
77/08 and SASL 29). Ann Oncol 2016;27:856-61. advanced hepatocellular carcinoma: multicenter phase II So. LAR.
45. Lim HY, Heo J, Choi HJ, Lin CY, Yoon JH, Hsu C, Rau KM, study. Cancer Chemother Pharmacol 2010;66:837-44.
Poon RT, Yeo W, Park JW. A phase II study of the efficacy and 59. Petrini I, Lencioni M, Ricasoli M, Iannopollo M, Orlandini C, Oliveri
safety of the combination therapy of the MEK inhibitor refametinib F, Bartolozzi C, Ricci S. Phase II trial of sorafenib in combination
(BAY 86-9766) plus sorafenib for Asian patients with unresectable with 5-fluorouracil infusion in advanced hepatocellular carcinoma.
hepatocellular carcinoma. Clin Cancer Res 2014;20:5976-85. Cancer Chemother Pharmacol 2012;69:773-80.
46. Okazaki T, Honjo T. PD-1 and PD-1 ligands: from discovery to 60. Hsu CH, Shen YC, Lin ZZ, Chen PJ, Shao YY, Ding YH, Hsu C,
clinical application. Int Immunol 2007;19:813-24. Cheng AL. Phase II study of combining sorafenib with metronomic
47. Brahmer JR, Hammers H, Lipson EJ. Nivolumab: targeting PD-1 to tegafur/uracil for advanced hepatocellular carcinoma. J Hepatol
bolster antitumor immunity. Future Oncol 2015;11:1307-26. 2010;53:126-31.
48. Melero I, Sangro B, Yau TC, Hsu C, Kudo M, Crocenzi TS, Kim 61. Giuliani F, Febbraro A, Addeo R, Rizzi Jr D, Maiello E, Del Prete S,
TY, Choo S, Trojan J, Meyer T, Welling TH, Yeo W, Chopra Pisconti S, Colucci G. Sorafenib plus cisplatin and gemcitabine in the
A, Anderson J, Dela Cruz CM, Lang L, Jaclyn N, Tang H, El- treatment of advanced hepatocellular carcinoma (HCC): a phase II
120 Hepatoma Research ¦ Volume 3 ¦ June 15, 2017